Washington, Mar 21 (UNB)– A team of researchers has identified “the long-sought culprit” in the mystery behind a cell-signaling breakdown that triggers heart failure, agencies report. Working with lab animals and human heart cells, researchers revealed that an enzyme called PDE-9 interferes with the body’s natural “braking” system needed to neutralize stress on the heart and shows that the enzyme wreaks mischief by gobbling up a signaling molecule, cGMP, which normally stimulates the production of a heart-protective protein called PKG, known to shield the heart muscle from the ravages of disease-causing stress, such as long-standing high blood pressure. Naturally found in the gut, kidneys and brain, PDE-9 is already a prime suspect in neurodegenerative conditions such as Alzheimer’s, but the new study shows the enzyme’s footprints are also present in heart cells and markedly elevated in patients with heart failure, evidence that PDE-9 is a multitasking “offender” and a key instigator of heart muscle demise, the researchers say.
To understand the enzyme’s role, the scientists exploited the knowledge that heart muscle health is safeguarded by two separate mechanisms, or signaling pathways. Activated by two different chemicals, nitric oxide and natriuretic peptide, each pathway produces cGMP, which in turn stimulates the all-important heart muscle protector PKG. Most cases of heart failure, the researchers say, are fueled by breakdowns in both. Researcher David Kass said that the existence of two separate pathways with overlapping but distinct functions is nature’s insurance policy, a fail-safe redundancy to ensure that should one pathway falter, the other one can compensate and maintain heart muscle function.
Lead author Dong Lee added that like a play with multiple characters, heart muscle function is the result of a complex but perfectly synchronized interaction of several proteins, enzymes and hormones and the findings reveal that, like two subplots that converge in the end of the play, PDE-5 and PDE-9 are independent rogue operators, each leading to heart muscle damage but doing so through different means. Researchers also note that heart failure treatments blocking the activity of PDE-9 may be right around the corner, with drugs that inhibit PDE-9 already being tested for use in people with Alzheimer’s disease. In this study, such PDE-9 blockers not only stopped heart muscle enlargement and scarring in mice with heart failure, but they nearly reversed the effects of the disease. The study is published in the journal Nature.